Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

NCT00484276 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Pleural Mesothelioma

Interventions

DRUG: NGR-hTNF

Sponsor

AGC Biologics S.p.A.